Tags

Type your tag names separated by a space and hit enter

Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
Expert Opin Pharmacother. 2016 Dec; 17(17):2341-2349.EO

Abstract

INTRODUCTION

The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors. Ceftazidime-avibactam is one of the newest such combination antibiotics, which has been released for treatment of complicated intra-abdominal infections in combination with metronidazole. Areas covered: In this drug evaluation manuscript cIAI along with the chemistry, pharmacodynamics, pharmacokinetics, metabolism and clinical study results of ceftazidime-avibactam are reviewed. Expert opinion: The role of ceftazidime-avibactam in combination with metronidazole in the treatment of cIAI is still to be defined. Patients with cIAI known to be infected with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae would be clear candidates for treatment with this agent, as would patients infected with more common types of extended-spectrum β-lactamase producing Gram-negative pathogens if a carbapenem alternative were desired. At present, it is difficult to establish a clear group of patients with cIAI for whom initial empiric therapy with this agent would be warranted.

Authors+Show Affiliations

a Department of Acute and Critical Care Surgery , Washington University School of Medicine , Saint Louis , USA.b Department of Pharmacy, Infectious Diseases Clinical Pharmacy Specialist , Barnes-Jewish Hospital , Saint Louis , USA.c Department of Medical Microbiology , Medical Centre Haaglanden-Bronovo , The Hague , The Netherlands.a Department of Acute and Critical Care Surgery , Washington University School of Medicine , Saint Louis , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27758148

Citation

Buckman, Sara A., et al. "Ceftazidime-avibactam for the Treatment of Complicated Intra-abdominal Infections." Expert Opinion On Pharmacotherapy, vol. 17, no. 17, 2016, pp. 2341-2349.
Buckman SA, Krekel T, Muller AE, et al. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2016;17(17):2341-2349.
Buckman, S. A., Krekel, T., Muller, A. E., & Mazuski, J. E. (2016). Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert Opinion On Pharmacotherapy, 17(17), 2341-2349.
Buckman SA, et al. Ceftazidime-avibactam for the Treatment of Complicated Intra-abdominal Infections. Expert Opin Pharmacother. 2016;17(17):2341-2349. PubMed PMID: 27758148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. AU - Buckman,Sara A, AU - Krekel,Tamara, AU - Muller,Anouk E, AU - Mazuski,John E, Y1 - 2016/10/31/ PY - 2016/11/1/pubmed PY - 2017/2/28/medline PY - 2016/11/1/entrez KW - Antibiotic resistance KW - ceftazidime-avibactam KW - complicatedintra-abdominal infections KW - β-lactam-β-lactamase inhibitors SP - 2341 EP - 2349 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 17 IS - 17 N2 - INTRODUCTION: The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors. Ceftazidime-avibactam is one of the newest such combination antibiotics, which has been released for treatment of complicated intra-abdominal infections in combination with metronidazole. Areas covered: In this drug evaluation manuscript cIAI along with the chemistry, pharmacodynamics, pharmacokinetics, metabolism and clinical study results of ceftazidime-avibactam are reviewed. Expert opinion: The role of ceftazidime-avibactam in combination with metronidazole in the treatment of cIAI is still to be defined. Patients with cIAI known to be infected with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae would be clear candidates for treatment with this agent, as would patients infected with more common types of extended-spectrum β-lactamase producing Gram-negative pathogens if a carbapenem alternative were desired. At present, it is difficult to establish a clear group of patients with cIAI for whom initial empiric therapy with this agent would be warranted. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/27758148/Ceftazidime_avibactam_for_the_treatment_of_complicated_intra_abdominal_infections_ L2 - https://www.tandfonline.com/doi/full/10.1080/14656566.2016.1249847 DB - PRIME DP - Unbound Medicine ER -